Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation

Clinics

Volumn 67, Issue 6, 2012, Pages 543-546

  Mansur, Antonio de Padua ^a   Takada, Julio Yoshio ^a   Avakian, Solange Desiree ^a   Strunz, Celia M C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anticoagulation; Chronic Atrial Fibrillation; Elderly; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGE; AGED; ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; CHRONIC DISEASE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; REFERENCE VALUE; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; REFERENCE VALUES; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84866322610     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(06)01     Document Type: Article

References (24)

1. Zimerman LI, Fenelon G, Martinelli Filho M, Grupi C, Atié J, Lorga Filho A, et al. Sociedade Brasileira de Cardiologia. Diretrizes Brasileiras de Fibrilação Atrial. Arq Bras Cardiol 2009;92(6 supl.1):1-39.
2. Stoddard MF, Singh P, Dawn B, Longaker RA. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J. 2003;145(4):676-82, http://dx.doi.org/10.1067/mhj.2003.91.
3. Mesas CE, Veloso HH, De Paola AA. Anticoagulation for atrial fibrillation: underutilization in a Brazilian tertiary outpatient clinic. Clin Cardiol. 2004;27(11):592-3.
4. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States. J Manage Care Pharm. 2009;15(3):244-52.
5. Blackshear JL, Baker VS, Rubino F, Safford R, Lane G, Flipse T, et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633-8.
6. Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18): 2282-9, http://dx.doi.org/10.1093/eurheartj/ehr134.
7. Fang MC, Chang YC, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141(10):745-52.
8. Chan PS, Maddox TM, Tang FM, Spinler S, Spertus JA. Practice-Level Variation in Warfarin Use Among Outpatients With Atrial Fibrillation (from the NCDR PINNACLE Program). American Journal of Cardiology. 2011;108(8):1136-40, http://dx.doi.org/10.1016/j.amjcard.2011.06.017.
9. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemostasis. 2011;106(5):968-77, http://dx.doi.org/10.1160/TH11-05-0353.
10. Primer of Biostatistics, version 4.02. McGraw-Hill Companies, New York, 1996.
11. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control-Results from SPORTIF III and IV. Arch Intern Med. 2007;167(3):239-45, http://dx.doi.org/10.1001/archinte.167.3.239.
12. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124(1):37-41, http://dx.doi.org/10.1016/j.thromres.2008.09.016.
13. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91(4):472-7, http://dx.doi.org/10.1136/hrt.2004.042465.
14. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Am J Med. 2010;123(7):638-86, http://dx.doi.org/10.1016/j.amjmed.2009.11.025.
15. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventionalintensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. New Engl J Med. 2003;349(7):631-9, http://dx.doi.org/10.1056/NEJMoa035422.
16. Singer DE, Chang YC, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation? The ATRIA Study. Circ-Cardiovasc Qual. 2009;2(4):297-30.
17. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA: the journal of the American Medical Association. 2011;306(11):1215-23, http://dx.doi.org/10.1001/jama.2011.1332.
18. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009;114(5):952-6, http://dx.doi.org/10.1182/blood-2009-02-207928.
19. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010;8(4):744-9, http://dx.doi.org/10.1111/j.1538-7836.2010.03756.x.
20. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curbs AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-Executive summary. J Am Coll Cardiol. 2006; 48(4):854-906.
21. Rudd KM, Dier JG. Comparison of Two Different Models of Anticoagulation Management Services with Usual Medical Care. Pharmacotherapy. 2010;30(4):330-8, http://dx.doi.org/10.1592/phco.30.4.330.
22. Hall D, Buchanan J, Helms B, Eberts M, Mark S, Manolis C, et al. Health Care Expenditures and Therapeutic Outcomes of a Pharmacist-Managed Anticoagulation Service versus Usual Medical Care. Pharmacotherapy. 2011;31(7):686-94, http://dx.doi.org/10.1592/phco.31.7.686.
23. Griffin BL, Burkiewicz JS, Peppers LR, Warholak TL. International Normalized Ratio values in group versus individual appointments in a pharmacist-managed anticoagulation clinic. Am J Health-Syst Ph. 2009;66(13):1218-23, http://dx.doi.org/10.2146/ajhp080278.
24. Watzke HH, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B. A prospective controlled trial comparing weekly self-testing and selfdosing with the standard management of patients on stable oral anticoagulation. Thromb Haemostasis. 2000;83(5):661-5.